GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sinclair Pharma PLC (XPAR:SPH) » Definitions » Research & Development

Sinclair Pharma (XPAR:SPH) Research & Development : €0.00 Mil (TTM As of Jun. 2018)


View and export this data going back to . Start your Free Trial

What is Sinclair Pharma Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Sinclair Pharma's Research & Development for the six months ended in Jun. 2018 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2018 was €0.00 Mil.

Sinclair Pharma Research & Development Historical Data

The historical data trend for Sinclair Pharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinclair Pharma Research & Development Chart

Sinclair Pharma Annual Data
Trend Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14 Jun15 Dec17
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sinclair Pharma Semi-Annual Data
Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Jun17 Dec17 Jun18
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Sinclair Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2018 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinclair Pharma  (XPAR:SPH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Sinclair Pharma Research & Development Related Terms

Thank you for viewing the detailed overview of Sinclair Pharma's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinclair Pharma (XPAR:SPH) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sinclair Pharma PLC (XPAR:SPH) » Definitions » Research & Development
Comparable Companies
XKRX:016580 XKRX:001360 ROCO:6576 ROCO:6472 TPE:1720 TSXV:FLWR XKRX:003060 XKRX:102460 AVDL XKLS:7148 XMAD:RJF XCNQ:OH TSX:RIV BOM:506197 SLDB SHSE:603139 TSX:TGOD SZSE:300254 LSE:AMYT OSTO:ORX
Traded in Other Exchanges
N/A
Address
Website
http://www.sinclairispharma.com
Sinclair Pharma PLC is a United Kingdom-based specialty pharmaceutical company focused on Dermatology, in particular, Aesthetics, Wound care, and Skin care. The group has a direct sales and marketing presence in the top five European markets and a rapidly growing International division concentrated on key emerging markets through long-term multi-product, multi-country, sales & marketing and distribution deals with key strategic partners. The Company's reportable operating segments are International Operations, France, Italy, Germany, UK, and Spain.